Company intelligence / Profile preview

Eveliqure Biotechnologies

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

Eveliqure’s lead candidate "ShigETEC" has completed preclinical studies showing significant immunogenicity and safety. It has entered Phase I clinical trials in Bangladesh and the USA targeting both shigellosis and ETEC-related diarrhoea. A NIAID contract was awarded to support ongoing Phase II studies. The company’s approach aims to provide broad protection against major causes of bacterial diarrhoeal disease.

Therapeutic areas: Infectious Diseases
Modalities: Live attenuated vaccinesbacterial vaccinessynthetic vaccines
Industry: Biotech

Drug pipeline

1 asset

ShigETEC

Partnerships

NIAID contract for clinical development funding; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on Eveliqure Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eveliqure Biotechnologies.